Moleculin Biotech - MBRX Short Interest Ratio & Short Volume

Short interest is the volume of Moleculin Biotech shares that have been sold short but have not yet been covered or closed out. As of February 28th, traders have sold 43,200 shares of MBRX short. 0.15% of Moleculin Biotech's shares are currently sold short. Learn More on Moleculin Biotech's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.15% of Moleculin Biotech's floating shares are currently sold short.

Moleculin Biotech saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 43,200 shares, a decrease of 30.1% from the previous total of 61,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Moleculin Biotech currently has issued a total of 28,630,000 shares. Some of Moleculin Biotech's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Moleculin Biotech currently has a public float of 27,880,000 shares.

0.15% of Moleculin Biotech's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Moleculin Biotech: Lipocine Inc. (1.50%), Eledon Pharmaceuticals, Inc. (0.12%), Neoleukin Therapeutics, Inc. (0.72%), Immix Biopharma, Inc. (2.00%), Lumos Pharma, Inc. (3.87%), SELLAS Life Sciences Group, Inc. (6.27%), Flora Growth Corp. (1.74%), TFF Pharmaceuticals, Inc. (0.67%), Satsuma Pharmaceuticals, Inc. (0.94%), and Novan, Inc. (2.17%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Suncor Energy Inc. ($3.27 billion), Occidental Petroleum Co. ($2.77 billion), Coinbase Global, Inc. ($2.25 billion), T. Rowe Price Group, Inc. ($2.23 billion), Paramount Global ($1.92 billion), Etsy, Inc. ($1.75 billion), Voya Financial, Inc. ($1.74 billion), CarMax, Inc. ($1.62 billion), Old Dominion Freight Line, Inc. ($1.62 billion), and Royal Caribbean Cruises Ltd. ($1.39 billion). View all of the most shorted stocks.

Short selling MBRX is an investing strategy that aims to generate trading profit from Moleculin Biotech as its price is falling. MBRX shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Moleculin Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MBRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MBRX, twice per month. The most recent reporting period available is February, 28 2023.